Periadolescent exposure to cannabinoids alters the striatal and hippocampal dopaminergic system in the adult rat brain

European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
A Higuera-MatasE Ambrosio

Abstract

In a previous work, we have shown that chronic administration of the cannabinoid agonist CP 55,940 (CP) during periadolescence increases cocaine self-administration in adult female rats, while it produces no such effect in males (Higuera-Matas et al., 2008). To extend these findings, we have analysed here the brains of the rats used as subjects in this previous work to evaluate the impact of the interaction between CP exposure and cocaine self-administration on dopaminergic parameters. We evaluated the levels of the dopamine transporter (DAT), and the D1- (D1R) and D2-type (D2R) dopaminergic receptors, as well as tyrosine hydroxylase (TH) mRNA in dopaminergic areas of the adult, cocaine self-administered, rat brain that had been chronically exposed to CP or vehicle (VH) during periadolescence. Control groups with CP/VH exposure and no self-administration experience were also included. In adult females, CP administration induced an up-regulation of DAT in the caudate-putamen that was maintained after cocaine self-administration. In males, CP induced an increase in the D1Rs content in the nucleus accumbens shell, which was not evident after cocaine self-administration. CP also reduced the expression of D2Rs in CA1 irrespective of...Continue Reading

References

Aug 1, 1991·Pharmacology, Biochemistry, and Behavior·D R BrittonD Kerkman
Jul 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·G Di Chiara, A Imperato
Sep 15, 1993·Biological Psychiatry·J H Meador-WoodruffS J Watson
Feb 1, 1993·Neuroreport·F Rodríguez de FonsecaJ J Fernández-Ruiz
Sep 17, 1996·Proceedings of the National Academy of Sciences of the United States of America·N D VolkowJ Lieberman
Jun 14, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Michael A NaderLinda J Porrino
Jun 18, 2002·Journal of Neurochemistry·Deborah C MashSari Izenwasser
Jul 9, 2002·Brain Research. Developmental Brain Research·Eva M RomeroM Paz Viveros
Mar 26, 2003·Psychopharmacology·Peter W Kalivas, Krista McFarland
Jan 30, 2004·Annual Review of Medicine·Jennifer Chao, Eric J Nestler
Feb 10, 2004·Psychopharmacology·Matthew G QuinlanRobert Ranaldi
Mar 17, 2004·Neuroscience and Biobehavioral Reviews·Linda J PorrinoMichael A Nader
Apr 16, 2004·Behavioural Brain Research·Yolanda D BlackKathleen M Kantak
Nov 6, 2004·Neuroscience and Biobehavioral Reviews·Megan E RothMarilyn E Carroll
Nov 16, 2004·Annals of the New York Academy of Sciences·F Scott HallGeorge R Uhl
Jun 1, 2005·Pharmacology, Biochemistry, and Behavior·Jonathon C Arnold
Jun 17, 2005·Life Sciences·Rebecca M Craft
Aug 16, 2005·Journal of Chemical Neuroanatomy·Ken W S Ashwell, George Paxinos
Feb 14, 2006·Brain Research·Jian-Ping GongGeorge R Uhl
Feb 18, 2006·Trends in Neurosciences·Rafael MaldonadoFernando Berrendero
Mar 22, 2006·Addiction·Denise B KandelLaura Cousino Klein
Mar 22, 2006·Addiction·David M FergussonL John Horwood
Mar 24, 2006·The European Journal of Neuroscience·M BeltramoA Reggiani
Jul 11, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Maria EllgrenYasmin L Hurd
Jan 26, 2007·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Joseph F CheerR Mark Wightman
Feb 13, 2007·European Journal of Pharmacology·Belen FerrerFernando Rodríguez de Fonseca
Feb 14, 2007·Experimental and Clinical Psychopharmacology·Kathleen M KantakValeria Uribe
Mar 14, 2007·The Journal of Pharmacology and Experimental Therapeutics·James K RowlettRoger D Spealman
Jun 7, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Alejandro Higuera-MatasEmilio Ambrosio
Oct 2, 2007·Frontiers in Neuroendocrinology·Jill B Becker, Ming Hu

❮ Previous
Next ❯

Citations

May 12, 2015·Neuroscience and Biobehavioral Reviews·Alejandro Higuera-MatasEmilio Ambrosio
Apr 8, 2016·Nature Reviews. Neuroscience·H Valerie CurranLoren H Parsons
Oct 15, 2013·Pharmacology, Biochemistry, and Behavior·Sarah M Minney, Hassan H López
Sep 11, 2016·The American Journal of Drug and Alcohol Abuse·Rebecca C HannaSubroto Ghose
Jul 27, 2012·The Australian and New Zealand Journal of Psychiatry·Anand GururajanMaarten van den Buuse
Jul 20, 2011·Journal of Psychopharmacology·Tiziana RubinoDaniela Parolaro
Sep 6, 2011·Journal of Psychopharmacology·Paul R A StokesAnne R Lingford-Hughes
Mar 6, 2018·Current Addiction Reports·Katina C CalakosKelly P Cosgrove
Jul 28, 2020·The International Journal of Neuropsychopharmacology·Enzo Javier Pérez-ValenzuelaJosé Antonio Fuentealba Evans
Dec 14, 2018·Frontiers in Molecular Neuroscience·Emma LeishmanHeather B Bradshaw
Jul 16, 2021·Journal of the International Neuropsychological Society : JINS·Ryan M SullivanKrista M Lisdahl

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.